One of the great challenges of cancermedicine is to develop effective treatments for bonemetastatic cancer.Most patients with advanced solid tumorswill develop bone metastasis andwill suffer fromskeletal related events associated with this disease. Although some therapies are available to manage symptoms derived from bone metastases, an effective treatment has not been developed yet. The mammalian target of rapamycin (mTOR) pathway regulates cell growth and survival. Alterations in mTOR signaling have been associated with pathological malignancies, including bone metastatic cancer. Inhibition of mTOR signalingmight therefore be a promising alternative for bonemetastatic cancermanagement. This review summarizes the current knowledge onmTOR pathway signaling in bone tissue and provides an overview on the known effects of mTOR inhibition in bone cancer, both in in vitro and in vivo models.
Targeting bone metastatic cancer: Role of the mTOR pathway
SILVESTRIS, Francesco;
2014-01-01
Abstract
One of the great challenges of cancermedicine is to develop effective treatments for bonemetastatic cancer.Most patients with advanced solid tumorswill develop bone metastasis andwill suffer fromskeletal related events associated with this disease. Although some therapies are available to manage symptoms derived from bone metastases, an effective treatment has not been developed yet. The mammalian target of rapamycin (mTOR) pathway regulates cell growth and survival. Alterations in mTOR signaling have been associated with pathological malignancies, including bone metastatic cancer. Inhibition of mTOR signalingmight therefore be a promising alternative for bonemetastatic cancermanagement. This review summarizes the current knowledge onmTOR pathway signaling in bone tissue and provides an overview on the known effects of mTOR inhibition in bone cancer, both in in vitro and in vivo models.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
